| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(16)00066-1 |
| P8608 | Fatcat ID | release_pnaep3q36vft5icyfpcre5ric4 |
| P698 | PubMed publication ID | 27106073 |
| P2093 | author name string | Fabrizio Benedetti | |
| Elisa Carlino | |||
| Alessandro Piedimonte | |||
| P2860 | cites work | Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome | Q21133920 |
| Lacosamide for neuropathic pain and fibromyalgia in adults | Q24203727 | ||
| Parkinson's disease gene therapy: success by design meets failure by efficacy | Q26851325 | ||
| Placebo effects: from the neurobiological paradigm to translational implications | Q26996428 | ||
| Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder | Q28251587 | ||
| Potentiation of placebo analgesia by proglumide | Q28283820 | ||
| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 | ||
| Lessons learned from placebo groups in antidepressant trials | Q28478927 | ||
| Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies | Q28542404 | ||
| Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication | Q28745052 | ||
| Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial | Q33628834 | ||
| Safety and tolerability of putaminal AADC gene therapy for Parkinson disease | Q33731687 | ||
| Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies | Q33761452 | ||
| Socially induced placebo analgesia: a comparison of a pre-recorded versus live face-to-face observation | Q33769926 | ||
| Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database | Q33898438 | ||
| Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease | Q34086449 | ||
| Placebo response in studies of major depression: variable, substantial, and growing | Q34122652 | ||
| Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches | Q34158126 | ||
| A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease | Q34209755 | ||
| Overt versus covert treatment for pain, anxiety, and Parkinson's disease | Q34359487 | ||
| Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial | Q44832150 | ||
| Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials | Q45181057 | ||
| Hidden administration of drugs | Q46714765 | ||
| Nocebo effects in multiple sclerosis trials: a meta-analysis | Q46822234 | ||
| Illness by suggestion: expectancy, modeling, and gender in the production of psychosomatic symptoms | Q47811043 | ||
| Pain and the context | Q47912833 | ||
| A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). | Q48742900 | ||
| The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning. | Q50479720 | ||
| Placebo analgesia induced by social observational learning. | Q50600120 | ||
| Creating placebo responders and nonresponders in the laboratory: boons and banes. | Q50653849 | ||
| Nocebo hyperalgesia induced by social observational learning. | Q50742963 | ||
| Placebo response in depression: bane of research, boon to therapy. | Q55034604 | ||
| Response expectancy as a determinant of experience and behavior | Q55924357 | ||
| For Placebo Effects in Medicine, Seeing Is Believing | Q57850432 | ||
| Placebo Effects in Medicine | Q60304535 | ||
| Clinical trial outcome in neuropathic pain: Relationship to study characteristics | Q60678746 | ||
| Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors | Q60688268 | ||
| Objective changes in motor function during placebo treatment in PD | Q64796855 | ||
| Effectiveness versus efficacy: more than a debate over language | Q73336821 | ||
| An extension of control group design | Q80311034 | ||
| Mechanisms involved in placebo and nocebo responses and implications for drug trials | Q85047394 | ||
| Trial design issues and treatment effect modeling in multi‐regional schizophrenia trials | Q85097129 | ||
| Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials. | Q34388991 | ||
| Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway | Q34400035 | ||
| Placebos and painkillers: is mind as real as matter? | Q34431140 | ||
| FAAH selectively influences placebo effects | Q34461780 | ||
| The double-blind variable placebo lead-in period: results from two antidepressant clinical trials | Q34474851 | ||
| Increasing placebo responses over time in U.S. clinical trials of neuropathic pain | Q34491005 | ||
| The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain | Q34606885 | ||
| Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions | Q34743030 | ||
| A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. | Q34893258 | ||
| Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association | Q34917757 | ||
| Seeing facial expressions enhances placebo analgesia. | Q35062225 | ||
| The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach | Q35111772 | ||
| Different Placebos, Different Mechanisms, Different Outcomes: Lessons for Clinical Trials | Q35832190 | ||
| Placebo effects on human mu-opioid activity during pain | Q35846183 | ||
| Dissociable influences of opiates and expectations on pain | Q36070260 | ||
| Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? | Q36119267 | ||
| Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain | Q36356568 | ||
| Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients | Q37027502 | ||
| A primer on effectiveness and efficacy trials | Q37549837 | ||
| A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
| Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis | Q37610143 | ||
| Placebo and the new physiology of the doctor-patient relationship | Q37655894 | ||
| Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
| Drugs and placebos: what's the difference?: Understanding the molecular basis of the placebo effect could help clinicians to better use it in clinical practice | Q37707506 | ||
| The placebo effect: From concepts to genes. | Q37723087 | ||
| Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice | Q37942656 | ||
| Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review | Q37984188 | ||
| The placebo response in medicine: minimize, maximize or personalize? | Q38085499 | ||
| Nocebo vs. placebo: the challenges of trial design in analgesia research | Q38351533 | ||
| Genetics and the placebo effect: the placebome | Q38425277 | ||
| What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? | Q40055789 | ||
| Placebo influences on dyskinesia in Parkinson's disease | Q40136999 | ||
| Placebo and opioid analgesia-- imaging a shared neuronal network | Q42162385 | ||
| Activation of the opioidergic descending pain control system underlies placebo analgesia. | Q43285483 | ||
| A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. | Q43662938 | ||
| The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil | Q44349496 | ||
| A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 | ||
| P433 | issue | 7 | |
| P921 | main subject | placebo | Q269829 |
| nocebo | Q1332954 | ||
| P304 | page(s) | 736-747 | |
| P577 | publication date | 2016-04-19 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects | |
| P478 | volume | 15 |
| Q47202221 | 'Caution, this treatment is a placebo. It might work, but it might not': why emerging mechanistic evidence for placebo effects does not legitimise complementary and alternative medicines in sport |
| Q64084870 | A Copernican Approach to Brain Advancement: The Paradigm of Allostatic Orchestration |
| Q55252484 | Accurate pain reporting training diminishes the placebo response: Results from a randomised, double-blind, crossover trial. |
| Q58747426 | Brain and psychological determinants of placebo pill response in chronic pain patients |
| Q92850729 | Can Insights From Placebo and Nocebo Mechanism Studies Help Improve Randomized Controlled Trials? |
| Q49721453 | Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System |
| Q47555962 | Clinical relevance of contextual factors as triggers of placebo and nocebo effects in musculoskeletal pain. |
| Q93061667 | Effectiveness of a tailored, integrative Internet intervention (deprexis) for depression: Updated meta-analysis |
| Q55394934 | Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). |
| Q58555579 | How do placebos work? |
| Q57556808 | How placebo characteristics can influence estimates of intervention effects in trials |
| Q28069705 | Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases |
| Q90732566 | Neuroimaging Studies of Antidepressant Placebo Effects: Challenges and Opportunities |
| Q38736906 | Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials |
| Q92665801 | Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial |
| Q92644323 | Pain, placebo, and test of treatment efficacy: a narrative review |
| Q103002620 | Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders |
| Q52776632 | Placebos in clinical trials: unravelling a complex phenomenon - Authors' reply. |
| Q52776636 | Placebos in clinical trials: unravelling a complex phenomenon. |
| Q92634042 | Practice-Based Research in Complementary Medicine: Could N-of-1 Trials Become the New Gold Standard? |
| Q38759815 | Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial |
| Q46251724 | Studying placebo effects in model organisms will help us understand them in humans. |
| Q92764171 | The Dangerous Side of Placebo Research: Is Hard Science Boosting Pseudoscience? |
| Q90472112 | The impact of contextual factors on nursing outcomes and the role of placebo/nocebo effects: a discussion paper |
| Q91790752 | The need to investigate nocebo effects in more detail |
| Q48088458 | The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning |
| Q92413870 | Three randomized studies of dentine hypersensitivity reduction after short-term SnF2 toothpaste use |
| Q39408152 | What techniques might be used to harness placebo effects in non-malignant pain? A literature review and survey to develop a taxonomy |
| Q42110583 | Why We should Assess Patients' Expectations in Clinical Trials |
| Q100489476 | Why we need more research into the placebo response in psychiatry |
Search more.